Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patidegib Topical Gel in Non-Gorlin High Frequency Basal Cell Carcinoma
NCT04155190Phase 2Terminated
- Sponsor
- Sol-Gel Technologies
- Start
- Dec 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patidegib in basal cell carcinoma (BCC), sponsored by Sol-Gel Technologies. Started Dec 2019; status: terminated.
02
Drugs
patidegib
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT04155190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04155190.